C12N 2750/14033
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/14033 (Use of viral protein as therapeutic agent other than vaccine) appears on 7 US grants and 8 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 8
- Assignees
- 5
- Inventors
- 7
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 2 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 2 | 2 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency22 Aug 2023US 11,732,246 B2The Trustees of the University of Pennsylvania
- Murine parvovirus and uses thereof17 May 2022US 11,332,720 B2Centenary Institute of Cancer Medicine and Cell Biology
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency22 Sep 2020US 10,781,430 B2The Trustees of the University of Pennsylvania
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency21 Apr 2020US 10,626,382 B2The Trustees of the University of Pennsylvania
- Protoparvovirus and tetraparvovirus compositions and methods for gene therapy29 Feb 2024US 2024/0066080 A1Synteny Therapeutics, Inc.
- Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency28 Dec 2023US 2023/0416700 A1The Trustees of the University of Pennsylvania
- Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency3 Dec 2020US 2020/0377866 A1The Trustees of the University of Pennsylvania
- Novel murine parvovirus and uses thereof7 May 2020US 2020/0140829 A1Centenary Institute of Cancer Medicine and Cell Biology
- Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency7 Mar 2019US 2019/0071651 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency13US 9,890,365 B2The Trustees of the University of Pennsylvania · 2018
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency10US 10,167,454 B2The Trustees of the University of Pennsylvania · 2019
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency6US 10,626,382 B2The Trustees of the University of Pennsylvania · 2020
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency2US 10,781,430 B2The Trustees of the University of Pennsylvania · 2020
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency1US 11,732,246 B2The Trustees of the University of Pennsylvania · 2023